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Abstract In a context of day hospital care of cancer
patients, a protocol combining etoposide and carboplatin is
used in paediatrics. Disposable infusion devices can be
used to improve patient quality of life and to optimize
nursing time. Stability data are available for carboplatin in
these devices but not for etoposide. The aim of this study
was to determine the stability of etoposide solutions in
these devices by monitoring the changing etoposide con-
centration. To study the changing etoposide concentration,
we investigated three different concentrations, each in two
different solvents: sodium chloride (NaCl) 0.9 % and
dextrose 5 %, in Intermate disposable infusion devices.
Quantitative analyses were performed by high-performance
liquid chromatography coupled with ultraviolet (UV)
detection on samples collected over a 24-h study period.
The results showed that 100 mg/L etoposide solutions were
stable for 24 h in NaCl 0.9 % and for 12 h in dextrose 5 %,
whatever the temperature. The 400-mg/L solutions were
stable for 24 h in both diluents, whatever the temperature,
whereas the 600-mg/L solutions when diluted in NaCl
0.9 % and dextrose 5 % in water were stable for 8 and 6 h,
respectively. We found that precipitation was the main
phenomenon responsible for decreased etoposide concen-
trations. This study allowed us to conclude that etoposide
solutions prepared in Intermate infusion devices are stable
for day hospital administration in paediatrics. It will also
allow us to conduct a future clinical study that will focus on
the medico-economic feasibility of this protocol and on the
evaluation of patient and nurse satisfaction.
1 Introduction
In the context of day hospital care of cancer patients, some
chemotherapy preparations can be administered using dis-
posable infusion devices in order to improve the patient’s
quality of life. These devices are particularly useful for this
purpose in paediatrics as they provide young patients with
more mobility during drug administration, enabling them to
continue their social and educational programmes instead
of being bedridden. Disposable infusion devices consist in
a latex- and polyvinyl chloride (PVC)-free polyisoprene
elastomer reservoir along with an anti-ultraviolet (UV)
protective shell that can be worn around the waist.
In the Department of Paediatrics at Gustave Roussy, a
regimen combining etoposide and carboplatin (VP-Carbo)
was designed for day hospital paediatrics (DHP) treatment
of neuroblastomas or medulloblastomas in children. Cur-
rently, etoposide is administered via a 1-h infusion of a
diluted solution, while carboplatin is administered using a
disposable infusion device because stability data concern-
ing the latter drug are already available in the literature
[1, 2].
A. Klasen  R. Kessari  L. Mercier  A. Paci (&)
Service Interde´partemental de Pharmacologie et d’Analyse du
Me´dicament (SIPAM), Institut Gustave-Roussy, 114, rue
Edouard Vaillant, 94805 Villejuif Cedex, France
e-mail: angelo.paci@gustaveroussy.fr; angelo.paci@igr.fr
A. Klasen  L. Mercier  A. Paci
De´partement de Biologie et Pathologie me´dicales, Institut
Gustave-Roussy, 114, rue Edouard Vaillant, 94805 Villejuif
Cedex, France
R. Kessari  L. Mercier  C. Valade  R. Desmaris  A. Paci
De´partement de Pharmacie Clinique, Institut Gustave-Roussy,
114, rue Edouard Vaillant, 94805 Villejuif Cedex, France
J. Grill
De´partement de Cance´rologie de l’Enfant et de l’Adolescent,
Institut Gustave-Roussy, 114, rue Edouard Vaillant, 94805
Villejuif Cedex, France
Drugs R D (2014) 14:13–23
DOI 10.1007/s40268-014-0037-9
Etoposide (Fig. 1) is an antineoplastic agent, semi-syn-
thetically derived from podophyllotoxin (epipodophyllo-
toxin), which acts through the inhibition of DNA
topoisomerase II. It can be used as a single agent but is
more usually used in combined multi-agent regimens to
treat several malignancies: embryonic carcinoma of the
testis, small cell lung cancer (SCLC) and non-small cell
lung cancer (NSCLC), non-Hodgkin malignant lymphoma,
Hodgkin’s disease (intensified therapy) and acute leukae-
mia. In paediatrics, etoposide is mainly used to treat central
nervous system tumours such as neuroblastoma and
medulloblastoma.
Etoposide can be administered orally using 25- or 50-mg
capsules or via a slow intravenous perfusion (a 1- to 2-h
infusion) using a 20-mg/mL solution diluted in sodium
chloride or dextrose. The infusion should start within the
hour following its preparation. Dosages may range from 50
to 400 mg/m2/day over 1–8 days, but typical dosages are
from 50 to 150 mg/m2/day over 1–3 consecutive days of
treatment every 3 or 4 weeks. The oral dose is twice its
intravenous counterpart.
Regarding stability data, the summary of product char-
acteristics (SPC) for etoposide describes a solution pre-
pared in PVC infusion bags or polyethylene syringes. The
manufacturers recommend that the diluted solution be
stored up to 48 h at room temperature. Nevertheless, the
French Society of Oncology Pharmacy reported that
sodium chloride 0.9 % (NaCl 0.9 %) diluted solutions
stored at a temperature below 25 C and under ambient
light remain stable up to 96 h for a 200-mg/L concentration
and up to 24 h for a 400-mg/L concentration. Beijnen et al.
[3] reported that etoposide is supposed to be stable up to
96 h at 400 mg/L in a NaCl 0.9 % solution and in dextrose
5 % in water (D5W).
The stability studies previously carried out using infu-
sion bags filled with solutions reported that etoposide sta-
bility is a function of the pH (optimum pH between 4 and
5) [3]. Neither light nor the container had an impact on
solution stability [3, 4]. However, the temperature did have
an impact on the stability of the solution, since a room
temperature of 20–24 C was reportedly more suitable than
a refrigerated one (4–12 C) [5, 6]. Etoposide stability is
also concentration dependent without drug degradation.
Changes in content were reportedly due to the formation of
a fine white precipitate, which corresponds to pure trans-
etoposide [6]. Precipitation does not always appear but is
more frequent when concentrations exceed 400 mg/L [3].
The aim of this study was to determine the stability of
etoposide solutions in disposable infusion devices in order
to allow the use of DHP protocols. Such devices could
improve the quality of life of young patients and could
permit better management of day hospital room availabil-
ity, thereby reducing treatment costs through a decrease in
nursing time.
As the only available stability data on etoposide solu-
tions found in the literature concerned solutions in soft
infusion bags and since there are no data on etoposide
stability at 33 C, which is the temperature attained by the
solutions prepared in the devices worn around the patient’s
waist, we decided to investigate the stability of several
etoposide solutions in these devices.
The study was to be conducted over a period of 24 h, at
three different concentrations; 100, 400 and 600 mg/L, to
fulfil the clinical protocol for the paediatric day hospital.
The methodology consisted in monitoring changes in
concentration by high-performance liquid chromatography
coupled with ultraviolet spectrophotometric detection
(HPLC-UV) of a given number of samples per testing
condition. This technique makes it possible to detect deg-
radation products in order to explain any possible degra-
dation of etoposide over time. The objective was to obtain
an adequate stability period in order to be able to admin-
ister the preparation during the period, taking into account
the time required to prepare the solution for injection (i.e.
the time between the preparation and the end of adminis-
tration, being about 6 h), for the three concentration solu-
tions. A further aim of the study was to investigate the
physico-chemical phenomena involved in the stability of
etoposide solutions.
2 Materials and Methods
2.1 Materials
Etoposide solutions are prepared from an initial solution at
20 mg/mL of etoposide Teva injectable solution. To studyFig. 1 Chemical structure of etoposide
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changes in the active ingredient, the dilution solvents used
were NaCl 0.9 % and D5W from Fresenius Kabi (Louviers,
France). Thirty-six Intermate disposable infusion devices
from Baxter SAS (Maurepas, France) were used. Twelve
had a nominal volume of 100 mL (SV100) and 24 had a
nominal volume of 250 mL (LV100). For the degradation
study, 0.1 M hydrochloric acid (0.1 M HCl) and 0.1 M
sodium hydroxide (0.1 M NaOH) were provided by Pro-
labo-VWR International SA (Fontenay-sous-bois, France)
and 10 % hydrogen peroxide (10 % H2O2) by Cooper
(Melun, France). Eighteen borosilicate tubes with a
capacity of 10 mL were used. The mobile phase was
composed of ultrapure water; of HPLC grade acetonitrile
(ACN) and RP grade acetic acid at 99 % from Prolabo-
VWR International SA (Fontenay-sous-bois, France).
Water was produced by a USF Elga dialyser.
2.2 Methods
2.2.1 Chromatographic Conditions
The chromatographic system comprises a Merck-Hitachi
L2200 injector, a Merck-Hitachi pump L-7100, equip-
ped with an HPLC Nucleodur column (C18endcapped/
100 A˚/5 lm/250 9 4 mm), a Jasco 2075 PLUS UV
detector along with Merck-Hitachi HSM D-7000 software
for computerized processing. The mobile phase consisted
of a water/ACN/99 % acetic acid mixture (64/35/1, v/v/v).
Chromatographic separation was done at a 0.7 mL/min
flow rate, with detection conducted at a 288 nm wave-
length. The injected volume was 20 lL. The analysis took
10 min and etoposide retention time was 6.4 min (Fig. 2).
Chromatographic analysis makes it possible to identify one
or more compounds characterized by a chromatographic
peak and its retention time. The area under the peak rep-
resents the concentration of each compound. Thus, com-
ponent concentration in solution was monitored by
comparing peak areas against a calibration plot.
2.2.2 Validation of the Analytical Method
Validation is essential to demonstrate that the method is
adapted to its use. Validation was conducted by evaluating
common parameters defined by the International Confer-
ence on Harmonization (ICH) [7] such as specificity,
response function, linearity, accuracy, precision (repeat-
ability and intermediate precision) and limits of detection
(LOD) and quantification (LOQ). The parameters were
determined by the statistical analysis of six calibration
plots.
Fig. 2 Chromatograms of a
400-mg/L etoposide solution
and a NaCl 0.9 % blank
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2.2.2.1 Specificity Specificity was investigated by
comparing the chromatogram of a blank sample with
the chromatogram of the solution under study. HPLC is
a selective method that separates different components
on a column. The specificity of the method was asses-
sed by analysing an etoposide solution. Figure 2 shows
the chromatogram resulting from the injection of a
400 mg/L etoposide solution and of a blank sample of
NaCl 0.9 %.
2.2.2.2 Linearity The calibration range was constructed
based on 11 calibration standards (25, 50, 100, 150, 200,
250, 500, 750, 1,000, 1,250 and 1,500 mg/L). Linearity
was investigated for six calibration plots recorded on six
different days (one plot a day). The average equation
parameters for the six linear regressions were:
y ¼ 3;787; 945x þ 29;207 ðr2 ¼ 0:999Þ:
A statistic comparison of the calibration curves was
conducted through normalised analysis of variance.
Variances were found homogenous by a Bartlett–Levine
test (p \ 0.00001).
2.2.2.3 Accuracy Accuracy expresses the closeness of
agreement between the values accepted as conventionally
true (referred to as the standard) and an estimated value
(called the medium) obtained by applying the analysis
technique a number of times. As shown in Table 1, accu-
racy values expressed by the theoretical value were below
5 % except for the lowest quality control established at
6.7 %.
2.2.2.4 Precision Precision allows one to assess the
repeatability and intermediate precision. The latter are
expressed by the coefficients of variation of repeatability
and intermediate precision that do not exceed 4.9 and
2.6 %, respectively (Table 1).
2.2.2.5 Limits of Detection (LOD) and of Quantification
(LOQ) LODs and LOQs are determined by the slope
(a) and the standard deviation of the y intercept of the
linear regressions (SDb) of calibration plots. The computed
value of the LOD is equal to 14.1 mg/L
(LOD = 3.3 9 SDb/a) and that of the LOQ is equal to
42.8 mg/L (LOQ = 10 9 SDb/a) (Table 2).
2.3 Changing Concentration of the Active Ingredient
2.3.1 Preparation of Devices
Manufacturing was carried out under conditions consistent
with Good Manufacturing Practices [8] in sterile isolation
boxes. Etoposide solutions were prepared at three different
concentration levels: 100 mg/L, 400 and 600 mg/L.
Twelve Intermate SV100 disposable perfusion devices
were filled with 100-mg/L solutions, twelve Intermate
LV100 disposable perfusion devices with 400-mg/L solu-
tions and twelve Intermate LV100 disposable perfusion
devices with 600-mg/L solutions.
2.3.2 Sampling and Pre-analytical Treatment
The stability study was conducted over three consecutive
days (one per concentration). The first sample was col-
lected at H0, immediately after filling the device. The
following samples were collected at H2, H4, H6, H8, H12
and H24. The samples (n = 12) were analysed in duplicate
via the HPLC-UV chromatographic system. The samples
for the analysis were collected from each mobile perfusion
device using a luer syringe after bleeding air from the pipe,
under a laminar air flow hood. The samples (approximately
0.5 mL) were then placed directly in vials that were posi-
tioned in the chromatographic system (without prior dilu-
tion). Etoposide concentrations were determined against
the linear regression plot.
Table 1 Fidelity and accuracy data of the analytical method
Quality controls (mg/L) 35 180 220 900 1,100 1,350
Repeatability
CVr (%) 2.8 0.5 4.8 4.9 1.2 0.9
Bias (%) 6.7 4.5 6 4.4 0.5 0.2
Intermediate fidelity
CVi (%) 2.2 0.3 1.6 2.6 1.7 1.6
Bias (%) 2.3 2.1 0.1 0.6 -2 -2.1
Table 2 Calibration data and Detection and quantification Limits
Cal 1 Cal 2 Cal 3 Cal 4 Cal 5 Cal 6 Mean SD
Slope (a) 3,750,686 3,713,734 3,695,046 3,875,442 3,879,179 3,813,583 3,787,945.0 80,202.7
Intercept (b) 17,962.0 30,672.0 39,300.0 20,002.0 11,776.0 55,528.0 29,206.7 16,197.7
Determination coefficient (R2) 0.9999 0.9998 0.9998 0.9995 0.9995 0.9995 0.9997 0.0002
Limit of detection (mg/L) 14.1
Limit of quantification (mg/L) 42.8
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2.3.3 Etoposide and Determination of Related
Degradation Products
For the forced degradation study in 0.1 M HCl, 0.1 M
NaOH and 10 % H2O2 as recommended by ICH, 100-,
400- and 600-mg/L solutions were prepared in three
borosilicate tubes. The study was conducted over three
days. Ten microlitres of a 100-lL volume of the sample
were injected into the chromatographic system. The first
sample was analysed at H0 immediately after preparation
of solutions. The following samples were tested at H24 and
at H48.
2.3.4 Analysis of the Precipitation Phenomenon
The stability data available in the literature for etoposide in
solution in these diluents prepared in PVC soft bags sug-
gest that the main cause of decreased etoposide concen-
tration over time is a precipitation phenomenon. The
kinetics of the degradation process is reported to be
dependent largely on the concentration [6]. That is why we
conducted a further experiment to quantify this phenome-
non. The stability of the etoposide solution in the dispos-
able perfusion devices was studied in NaCl 0.9 % and in
D5W at 600 mg/L.
2.3.4.1 Sampling and Analytical Pre-treatment After
preparing the devices, a sample (S1) was tested at H0 in
order to determine the initial concentration of the solution.
A second sample (S2) was tested at H24 to quantify the
concentration in the device after 24 h. The samples were
placed in a vial and then directly into the chromatographic
system. A volume of 10 lL was injected.
At H24, we drilled through the balloon drug reservoir
via the shell of the device and recovered 100 mL of the
solution that were then placed in two 50 mL-Falcon
tubes (F1 and F2). The contents of each tube were cen-
trifuged for 5 min at 3,000 rpm; the supernatant was then
eliminated to obtain the precipitate. To obtain the whole
precipitate in the device, the inside of the shell and of the
balloon was rinsed twice with 10 mL of water using a
syringe with a needle (L1 and L2). L1, L2 and the pre-
cipitate were mixed and centrifuged for 5 min at
3,000 rpm. After elimination of the supernatant, the pre-
cipitate was dissolved in 25 mL of methanol. Concentra-
tions of etoposide methanolic solutions were determined
by HPLC-UV in the conditions described above. Finally,
the L1 and L2 samples were analysed by injecting 10 lL
into the chromatographic system. Etoposide concentra-
tions were determined to evaluate the efficiency of the
washing and thus the reliability of the precipitate recovery
method.
3 Results
3.1 Forced Degradation Study
Exposition of etoposide solutions to studied conditions led
to precipitation after 48 h for ambient and 33 C storage
conditions except for alkaline conditions, where coloration
of solution was observed instead of a precipitation.
Figure 3 shows results of the forced degradation study
for 600-mg/L etoposide solutions in various dissolution
media. Curve A shows the results of an injection of eto-
poside solution diluted in NaCl 0.9 %; curve B shows the
chromatogram resulting from the injection of a solution of
etoposide diluted in NaOH 0.1 M injected right after
dilution; curve C shows the chromatogram resulting from
the injection of a solution of etoposide diluted in H2O2
10 % after 48 h of exposition; curve D shows the chro-
matogram resulting from the injection of a solution of
etoposide diluted in HCL 0.1 M after 48 h of exposition;
curve E shows the chromatogram resulting from the
injection of a solution of etoposide diluted in NaOH 0.1 M
after 48 h of exposition. Exposition to alkaline conditions
yields a main degradation product eluted around 6.0 min,
its content is increased after 48 h of exposition. Exposition
to acidic conditions yields another degradation product
eluted around 4.0 min. Exposition to strong oxidative
conditions yields a degradation product eluted around
8.4 min. Therefore, the chromatographic method is able to
separate etoposide from its main degradation products.
Evolution of etoposide content in supernatant in differ-
ent stress testing conditions is shown in Fig. 4. Those
results show that etoposide content is greatly decreased in
the supernatant in acidic and alkaline conditions while it
remains stable in oxidative conditions. For alkaline con-
ditions, decrease in etoposide concentration is probably
caused by chemical degradation, as suggested by the
chromatographic elution of by-products of etoposide and
coloration of solution. For acidic conditions, it is unclear
whether the decrease is due to the precipitation phenome-
non or to a chemical degradation caused by stress factor, or
a combination of both. Those results are consistent with
previous observation of pH-related degradation of etopo-
side in solution [3].
3.2 Changing Concentration of the Active Ingredient
We decided to work with a confidence interval of ±5 %
(i.e. [95, 105 %] of the nominal value) for concentrations
in this study, although a confidence interval of ±10 % is
stipulated for hospital preparations (i.e. [90, 110 %]) in the
literature [9, 10]. For the sake of simplicity, by definition,
the value of 100 % represented the concentration values
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observed at H0. For the 100-mg/L concentration (Table 3),
we observed that the solution was stable for 24 h in the
NaCl 0.9 % and 12 h in the D5W, both at room tempera-
ture and at 33 C. Regarding the 400-mg/L solution, eto-
poside was stable for 24 h in both diluents, both at room
temperature and at 33 C (Table 4), which is consistent
with reported data [3, 5]. We retained a 24-h stability
period for NaCl 0.9 % and D5W solutions at 400 mg/L.
We observed dissimilar stability data for the 600-mg/L
solutions. Stability periods of 8 and 6 h were found for
NaCl 0.9 % and D5W solutions stored at room temperature
and at 33 C, respectively (Table 5). According to the lit-
erature [3–5], above 400 mg/L, etoposide concentrations
decrease dramatically, with precipitate formation resulting
in a 24-h stability period. In our study, the 600-mg/L
solutions were found to be stable up to 8 h at room tem-
perature and up to 6 h at 33 C (Fig. 5). It is noteworthy
that the temperature has an impact on etoposide stability,
especially in the case of high-concentration solutions.
Concentrations at 100 and 400 mg/L are suitable for
paediatric regimens, whereas the concentration of 600 mg/
L is intended for adults. The minimum stability period
required is approximately 5–6 h for the use of these dis-
posable perfusion devices in this context. If stability above
24 h is required, etoposide phosphate (Etopophos),
between 0.1 and 20 mg/mL in PVC bags [11], known to be
stable up to 48 h at 37 C, up to 96 h at 25 C and up to
7 days between 2 and 8 C in solution could be used.
However, no stability data are available concerning this
active substance in these devices.
As changes in the concentration did not reveal any
degradation products similar to those observed during
stress testing, whereas precipitation was observed, we
investigated the precipitation phenomenon.
3.3 Precipitation Phenomenon
3.3.1 Reliability of the Precipitate Recovery Method
Normalised etoposide data after quantification of the wash
solution (L1 and L2) yielded the following results. For
solutions in NaCl 0.9 % (samples 1–3), the average eto-
poside concentration found in L1 was 7.3 % of the initial
concentration and 3.3 % for L2. For solutions in D5W
(samples 4–6), the average etoposide concentration found
was 19.5 % of the initial concentration for L1 and 3.2 %
for L2. Using this method, overall recovery was 102.1 and
97.9 % of initial content of etoposide in D5W and NaCl
0.9 %, respectively. Moreover, less than 4.0 % of the ini-
tial content of etoposide was found in the second wash
elution, indicating a 96.0 % extraction yield for our
method. Thus, the recovery method was considered reliable
for our purpose.
Fig. 3 Chromatograms of
600-mg/L etoposide solution
submitted to various stress
testing of forced degradation
study
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Fig. 4 Changing concentration as a function of time 100-, 400- and 600-mg/L etoposide solutions exposed to various stress factors
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Table 3 Variation of the concentration values for the 100-mg/L etoposide solution
h 0 2 4 6 8 12 24
NaCl 0.9 %
RT
Mean 100.0 % 102.8 % 99.9 % 104.1 % 98.6 % 99.5 % 99.4 %
RSD 0.000 0.072 0.042 0.023 0.038 0.038 0.026
d (%) 0.0 2.8 -0.1 4.1 -1.4 -0.5 -0.6
33 C
Mean 100.0 % 100.6 % 101.1 % 98.9 % 98.4 % 99.3 % 99.6 %
RSD 0.000 0.003 0.013 0.001 0.001 0.001 0.003
d (%) 0.0 0.6 1.1 -1.1 -1.6 -0.7 -0.4
D5W
RT
Mean 100.0 % 99.9 % 98.5 % 99.1 % 99.5 % 101.1 % 93.7 %
RSD 0.000 0.013 0.012 0.019 0.001 0.011 0.012
d (%) 0.0 -0.1 -1.5 -0.9 -0.5 1.1 -6.3
33 C
Mean 100.0 % 100.2 % 100.9 % 99.7 % 100.7 % 98.3 % 93.8 %
RSD 0.000 0.007 0.016 0.003 0.009 0.012 0.019
d (%) 0.0 0.2 0.9 -0.3 0.7 -1.7 -6.2
The mean and RSD values were calculated on six different measurements. d is the variation between each time and H0
Italic values correspond to content shift [5 % between stability samples and native samples
D5W dextrose 5 % in water
Table 4 Variation of the concentration values for the 400-mg/L etoposide solution
h 0 2 4 6 8 12 24
NaCl 0.9 %
RT
Average 100.0 % 100.8 % 101.9 % 101.0 % 100.9 % 101.5 % 102.5 %
RSD 0.000 0.003 0.004 0.001 0.001 0.004 0.016
d (%) 0.0 0.8 1.9 1.0 0.9 1.5 2.5
33 C
Average 100.0 % 100.4 % 102.6 % 99.7 % 100.1 % 99.5 % 99.9 %
RSD 0.000 0.010 0.009 0.007 0.008 0.025 0.019
d (%) 0.0 0.4 2.6 -0.3 0.1 -0.5 -0.1
D5W
RT
Average 100.0 % 100.1 % 100.4 % 100.7 % 100.1 % 100.0 % 103.9 %
RSD 0.000 0.008 0.003 0.014 0.007 0.009 0.004
d (%) 0.0 0.1 0.4 0.7 0.1 0.0 3.9
33 C
Average 100.0 % 100.2 % 98.8 % 99.3 % 99.9 % 99.6 % 98.7 %
RSD 0.000 0.009 0.009 0.011 0.018 0.008 0.001
d (%) 0.0 0.2 -1.2 -0.7 -0.1 -0.4 -1.3
The mean and RSD values were calculated on six different measurements. d is the variation between each time and H0
D5W dextrose 5 % in water
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3.3.2 Results of the Precipitation Phenomenon
The quantitative results of the study are presented in
Table 6, taking into account a confidence interval of ±5 %
(i.e. [95, 105 %] of the nominal value) for the concentra-
tions. For the sake of simplicity, by definition, the value of
100 % represented the concentration values observed at
H0. The same retention time (6.97 min) found for each
assayed solution indicated that the substance forming the
precipitate and that in the solution were the same com-
pound (i.e. etoposide). This showed that the precipitate
found in the devices was etoposide, as previous studies
suggested. We observed a precipitate at H24 for the six
devices prepared.
For solutions in NaCl 0.9 % after 24 h, the amount of
etoposide (L1 ? L2) in solution (SNaCl) represented an
average of 37.0 % of the initial etoposide concentration,
while the concentration from the precipitate (PNaCl) rep-
resented an average of 65.2 % of the initial etoposide
concentration. For solutions in D5W after 24 h, the amount
of etoposide (L1 ? L2) in the solution (SD5) represented an
average of 42.4 % of the initial etoposide concentration,
while the concentration from the precipitate (PD5) repre-
sented an average of 55.5 % of the initial etoposide con-
centration. The decreased etoposide concentration in
disposable infusion devices was therefore only due to the
formation of an etoposide precipitate. This decrease in
concentration may be considered as entirely due to the
phenomenon of precipitation, and not to the formation of
degradation products.
4 Conclusion
Regarding changes in the concentration of the active sub-
stance, we can conclude that (i) in low-dose solutions
(100 mg/L), etoposide was stable up to 12 h in D5W and
up to 24 h in NaCl 0.9 %, both at room temperature and at
33 C; (ii) etoposide was stable up to 24 h in 400-mg/L
solutions, in NaCl 0.9 % and D5W, both at room temper-
ature and at 33 C; and (iii) etoposide was stable in
600-mg/L solutions for 8 h at room temperature and for 6 h
at 33 C, in NaCl 0.9 % and D5W.
After 24 h, quantification of the precipitate and of eto-
poside in solution showed that 100 % of the initial etoposide
concentration is recovered, with a 5 % confidence interval.
No known etoposide degradation products were found while
monitoring changes in the content of the active ingredient.
Moreover, the amount of etoposide found in the form of a
precipitate corresponded to the missing amount. This
allowed us to conclude that precipitation was the only cause
of instability in the etoposide solution in these devices.
This study allowed us therefore to conclude that eto-
poside was stable enough, especially at low and medium
Table 5 Variation of the concentration values for the 600-mg/L etoposide solution
h 0 2 4 6 8 12 24
NaCl 0.9 %
RT
Average 100.00 % 99.40 % 101.90 % 101.70 % 103.10 % 74.40 % 51.70 %
RSD 0.000 0.014 0.021 0.018 0.031 0.028 0.03
d (%) 0.0 -0.6 1.9 1.7 3.1 -25.6 -48.3
33 C
Average 100.00 % 100.30 % 100.80 % 100.50 % 91.20 % 68.90 % 50.40 %
RSD 0.000 0.005 0.016 0.005 0.004 0.012 0.021
d (%) 0.0 0.3 0.8 0.5 -8.8 -31.1 -49.6
D5W
RT
Average 100.00 % 100.00 % 99.80 % 100.00 % 99.20 % 89.20 % 71.30 %
RSD 0.000 0.001 0.003 0.005 0.001 0.05 0.038
d (%) 0.0 0.0 -0.2 0.0 -0.8 -10.8 -28.7
33 C
Average 100.00 % 100.00 % 101.70 % 102.40 % 106.80 % 99.80 % 65.60 %
RSD 0.000 0.008 0.012 0.019 0.076 0.048 0.019
d (%) 0.0 0.0 1.7 2.4 6.8 -0.2 -34.4
The mean and RSD values were calculated on six different measurements. d is the variation between each time and H0
Italic values correspond to content shift [5 % between stability samples and native samples
D5W dextrose 5 % in water
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Fig. 5 Changing concentration
as a function of time in 100-,
400- and 600-mg/L etoposide
solutions in infusion devices
Table 6 Distribution of etoposide in solution and in its precipitate form (600 mg/L)



















Sample 1 100 36.6 63.7 100.3 Sample 4 100 43.8 54.5 98.2
Sample 2 100 37.4 64.9 102.3 Sample 5 100 41.1 56.5 97.6
Sample 3 100 36.9 67.0 103.9 Sample 6 100 42.3 55.6 97.8
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concentrations, for use in disposable infusion devices such
as Intermate prepared in the Central Chemotherapy Pro-
duction Facility for day hospital administration in a Pae-
diatrics Unit. It will also allow our clinical team to conduct
a future clinical study that will focus on the medico-eco-
nomic feasibility of using these infusion devices and on the
evaluation of patient and nurse satisfaction.
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